Expert Interview: Using Single-Cell Proteomics to Enable the Adaptive and Innate Immune Response in Vaccines Against COVID-19

IsoPlexis
By IsoPlexis
/
April 3, 2020
/
Min. Read95 words
IsoPlexis

This week, IsoPlexis interviewed Moriya Tsuji, M.D., Ph.D., Professor of Medicine at Aaron Diamond AIDS Research Center, Columbia University. In the interview, Dr. Tsuji discusses:

  • Using more predictive single cell proteomics in mouse models to understand correlative T cell potency in infectious disease vaccines
  • How understanding of more predictive T cell potency in humanized mouse models is important for understanding vaccine development
  • The challenges in pre-clinical vaccine development today that can be overcome by having potency tools and better ways to characterize human immune response

Watch the full interview to learn more.

 

Moriya Tsuji

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

Latest from the IsoPlexis Data Network

Infectious Disease Roundtable
May 28, 2020
IsoPlexis’ Single-Cell Proteomics Tackles Vaccine Development: Roundtable Discussion from Leading Infectious Disease Researchers
Read More
,
May 21, 2020
A Multi-Omic Tour: Three Nature Publications on How Cells Communicate Via IsoPlexis’ Proteomics
Read More
Denis Wirtz
May 19, 2020
Understanding Cancer Cell Communication to Infer a Strategy to Inhibit Tumor Cell Migration: Webinar with Dr. Denis Wirtz of Johns Hopkins
Read More